By 01/05/2012 | Press Release
GREENWOOD VILLAGE, Colo. , Jan. 5, 2012 -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it will hold a Web Cast on Thursday, January 26, 2012 at 4:15 EST . The purpose of the call will be to update our shareholders on the company's progress and a press release on January 16th will announce how the shareholders and the general public can join and listen to the call.
The company will present a 30-minute overview of the company's progress and future plans and then open the call to a Q & A session. The subjects covered will include:
- Ampio's sexual dysfunction drug portfolio Zertane ™ , for the treatment of premature ejaculation (PE) and a combination drug that combines Zertane ™ and a PDE5 inhibitor for simultaneous treatment of PE and erectile dysfunction (ED)
- Ampio's anti-inflammatory drug Ampion ™ , and an update on the Australian clinical trial for the treatment of Osteoarthritis in the knee
- Ampio's vascular permeability drug Optina ™ , and an update on the Canadian Phase II clinical trial for the treatment of patients with Diabetic Macular Edema (DME), which is a common complication of Diabetes Mellitus
"Our progress in 2011 and our clinical plans going forward are difficult to explain in periodic press releases." said Michael Macaluso , Ampio's Chairman. "This format will allow a more nuanced presentation of the direction that Ampio has taken, as well as the short term future plans for each of our products."
Homework for shareholders
For those shareholders who would like to prepare for this webcast by reviewing a few of Dr. Bar-Or's peer-reviewed articles reporting early research on these products, please click on the articles below:
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.
Forward-Looking Statements
Ampio's statements made in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Contact
Investor Relations,
